SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today reviewed 2011 achievements and provided its outlook for 2012 at the JPMorgan 30th Annual Healthcare Conference.
In 2012, non-GAAP total revenue is targeted to increase approximately 15 percent year-over-year to a range of $5.4 to $5.6 billion. REVLIMID net product sales are expected to increase approximately 19 percent to a range of $3.75 to $3.85 billion. Non-GAAP diluted earnings per share (EPS) is targeted to increase approximately 25 percent to a range of $4.70 to $4.80. The EPS guidance assumes a constant share count from 2011 to 2012.
